111 Capital’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VRTX
111 Capital's VRTX Position: Q2 2026 in Review
111 Capital reduced its Vertex Pharmaceuticals (VRTX) stake by 18% in Q2 2026, selling an estimated $293K and leaving 3,080 shares worth $1.53M. The position accounts for 0.26% of the portfolio, ranked #78.
111 Capital first reported a position in VRTX in Q4 2024 and has held it in 5 quarters since. The position peaked at $1.71M in Q3 2025. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- 111 Capital held 3,080 shares of Vertex Pharmaceuticals worth $1.53M as of Q2 2026.
- 111 Capital sold 660 Vertex Pharmaceuticals shares in Q2 2026, an estimated $293K.
- Vertex Pharmaceuticals made up 0.26% of 111 Capital's portfolio in Q2 2026, its #78 holding.
- 111 Capital first reported a position in Vertex Pharmaceuticals in Q4 2024 and has held it in 5 quarters since.
- 111 Capital's Vertex Pharmaceuticals position peaked at $1.71M in Q3 2025.
- 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on 111 Capital's 13F filing for Q2 2026, filed 5 Aug 2026.